11.14.26 -- Cell & Gene Newsletter - Best of October

At Meeting on the Mesa 2026, industry leaders discussed what it will take to move autoimmune CAR T beyond promising clinical results.

The United States Pharmacopeia is rolling out new standards and tools to help manufacturers characterize fragile, complex lentiviral vectors.

Make smarter outsourcing decisions early. Reduce the risk of costly tech transfers, evaluate capacity needs, speed development timelines, and strengthen manufacturing partnerships.

Stay ahead of FDA QMSR, EU GMP, and AI regulations by adopting continuous audit readiness, ALCOA++ data integrity, and closed-loop workflows for global compliance.

Modern contamination control links barrier design, bio-decontamination science, and risk-based validation to ensure reliable surface sterility.

Discover how scalable, cost-effective, and high-quality lentiviral vector manufacturing can accelerate both ex vivo and emerging in vivo CAR-T therapies.